SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001140361-22-024164
Filing Date
2022-06-27
Accepted
2022-06-27 16:48:29
Documents
1
Period of Report
2022-06-23

Document Format Files

Seq Description Document Type Size
1 FORM 4 form4.html 4  
1 FORM 4 form4.xml 4 5293
  Complete submission text file 0001140361-22-024164.txt   6712
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Fust Matthew K (Reporting) CIK: 0001397266 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36548 | Film No.: 221045274

Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Issuer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences